VICTORY CAPITAL MANAGEMENT INC
Position in SYRE — Spyre Therapeutics, Inc.
CIK 1040188
San Antonio, TX
Position in SYRE
as of Jun 30, 2026
· filed Aug 7, 2026
Position Value
$49,182,344
+$34,447,509 QoQ
Shares Held
553,980
+89.6% QoQ
Ownership
0.628%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#37
of 266 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in SYRE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026VICTORY CAPITAL MANAGEMENT INC holds $2,534,997,913 across 158 Biotechnology names. SYRE ranks #9 (1.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
2,173,152 | $1,079,469,792 | |
| 2 | RPRX |
Royalty Pharma plc
|
3,682,932 | $206,501,997 | |
| 3 | INCY |
Incyte Corp
|
1,480,342 | $167,811,569 | |
| 4 | JAZZ |
Jazz Pharmaceuticals plc
|
686,719 | $165,478,677 | |
| 5 | LGND |
Ligand Pharmaceuticals Inc
|
253,764 | $80,212,262 | |
| 6 | REGN |
Regeneron Pharmaceuticals, Inc.
|
126,343 | $78,779,914 | |
| 7 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
172,842 | $52,030,627 | |
| 8 | BNTX |
BioNTech SE
|
539,787 | $50,227,180 |
All Filings in SYRE
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $49,182,344 | 553,980 | Shares | Sole | 2026-08-07 | |
| 2026-03-31 | $14,734,835 | 292,126 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $4,785,548 | 146,079 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $5,465,117 | 326,081 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $5,301,116 | 354,116 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $4,063,534 | 251,846 | Shares | Sole | 2025-05-02 | |
| 2024-12-31 | $6,240,809 | 268,076 | Shares | Other | 2025-02-06 | |
| No filing history on record for this holder in this stock. | ||||||